Insiders are buying Pfizer (PFE) stock, which is trading near 10-year lows with a high dividend yield, but revenue and earnings growth remain stagnant.
Source Post
Insiders Buying Pfizer Stock at a 52 Week Low! | Pfizer (PFE) Stock Analysis! |
Aug 11, 2026
Insiders have recently purchased Pfizer (PFE) stock for the first time in over 1.5 years, coinciding with the stock trading near 10-year lows and offering a high dividend yield of around 6.4%. Despite recent struggles and underperformance, the stock has seen a slight recovery this year. The analysis highlights stagnant revenue growth and a decline in earnings per share following the COVID-19 boom, with recent guidance suggesting continued revenue stagnation through 2026. The acquisition of Seagen is also noted as a factor impacting financials.
Linked Mentions
Tickers discussed in this post
Linked Signals
Tracked calls opened from this post
No linked signals were opened directly from this post.